The findings revealed a significant increase in the hypoxia index (GLUT1, one of the primary target genes regulated by hypoxia-inducing factor HIF-1) and up-regulation of CCL28 expression in lung adenocarcinoma patients 24 h after VEGF monoclonal antibody treatment compared to baseline levels (Fig. 1A, 1B). Here, SLC2A1 is linked to lung adenocarcinoma.